Business Context and Reporting Period
This Form 8-K Current Report was filed by Integer Holdings Corporation on February 24, 2023. The filing discloses specific executive compensation adjustments and equity transactions involving the Company's President and CEO, Joe Dziedzic, and its President, Cardio & Vascular, Payman Khales.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation events.
- Option Exercise (Joe Dziedzic): 14,530 shares acquired via cash payment of $366,883.
- Restricted Stock Units (Payman Khales): Special award with a grant date fair value of $2,000,000.
- Salary Adjustment (Payman Khales): Annual base salary increased from $450,000 to $550,000, effective March 20, 2023.
Material Changes
The filing details the following material changes regarding executive compensation and equity:
- CEO Option Exercise: Joe Dziedzic exercised options granted in 2013 that were set to expire on the filing date. No taxes were withheld on this transaction as the options were issued prior to his tenure as President and CEO.
- Executive Retention Package: Payman Khales received a new $2,000,000 RSU award vesting on February 24, 2026. Additionally, the vesting schedule for his November 2022 RSU grant was amended to vest entirely on February 24, 2026, rather than in installments.
- Compensation Increase: Mr. Khales' base salary was increased by $100,000 annually.
Outlook, Risks, and Management Commentary
Management stated that the new award and salary increase for Mr. Khales recognize his leadership and contributions. The primary objective of these changes is to retain Mr. Khales in his current position and incentivize him to drive future stock price growth.
Contingencies: The awards include a specific provision regarding involuntary termination following a change in the Chief Executive Officer. Under this condition, the awards will not be forfeited but will vest on a pro-rata basis based on Mr. Khales' length of service during the vesting period.
Investor Verification Checklist
- Verify the total number of shares outstanding post-exercise for Joe Dziedzic.
- Confirm the impact of the $2,000,000 RSU grant and salary increase on future non-GAAP compensation expense.
- Review the specific terms of the "change in CEO" vesting acceleration clause for Payman Khales.
- Check subsequent filings for any further changes to the vesting schedules mentioned in this report.